Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) - a tumor necrosis factor alpha (TNF-α) inhibitor

5 Oct 2015

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

U.S 2nd Annual Obesity Summit: 35 major U.S. health societies see how they can treat obesity

Representatives from 35 major health and medical organizations including, the American Diabetes Association (ADA), American Medical Association (AMA), American Heart Association (AHA), American Academy of Orthopaedic Surgeons (AAOS), and American Society of Clinical Oncology (ASCO) convened for a second annual summit in Chicago to identify opportunities for collaboration in treating obesity. “The National Obesity Summit on the Provision of Care for the Obese Patient” was hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS).

4 Oct 2015

Preoperative MRI use increasing in breast cancer

A Canadian research team reports a substantial increase in the use of preoperative magnetic resonance imaging over a 10-year period in women with newly diagnosed breast cancer.

2 Oct 2015

Self-reported fatigue predicts myelodysplastic syndromes survival

Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.

1 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

Primary care doctors ill-prepared to cope with rising demand for cancer care in high-income countries

Leading primary care professionals and cancer experts will warn at the Royal College of General Practitioners annual congress in Glasgow, UK that primary care doctors will not be able to cope with the rising demand for cancer care in high-income countries – predicted to double within the next 15 years.

1 Oct 2015

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

The results show that Oraya Therapy is effective in maintaining vision with reduced injections for patients at different stages of their disease—from chronic patients in discontinuous treatment to treatment-naive patients with new diagnosis—and following different treatment pathways.

1 Oct 2015

Researchers roll out updated online breast cancer risk calculator

Growing up, Charlotte Gard knew she came from a long line of women who developed breast cancer. The New Mexico State University assistant professor always expected her mother to develop it, like her grandmother before her, so she knew she wanted to contribute to research that would help fight the disease that kills more than 40,000 women in the U.S. every year.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Stony Brook Children's Hospital follows pain management protocols to treat pain in pediatric patients

Stony Brook Children's Hospital clinicians follow pain management protocols to proactively, preemptively, and consistently treat pain in each and every pediatric patient. Known as the Ouchless Approach to Pediatric Medicine, Margaret McGovern, MD, PhD, Physician-in-Chief, describes it as the cornerstone of treatment for pediatric patients at Stony Brook Children's.

30 Sep 2015

Intratumoral morphological diversity of breast cancer not related to chromosome aberrations

Intratumor morphological heterogeneity (diversity) of breast cancer is not related to chromosome aberrations. This conclusion was made based on the study of one case with aggressive variant of breast cancer - invasive micropapillary carcinoma by researchers from Tomsk State University, Tomsk Cancer Research Institute, and Institute of Medical Genetics.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

MedUni Vienna researchers report new strategy for targeted treatment of ovarian cancer

A team of researchers at the MedUni Vienna has confirmed in a recent study its new concept for the targeted treatment of ovarian cancer. The concept is intended to better control the development of resistance and improve treatment outcomes.

29 Sep 2015

Majority of cancer patients lack access to safe, affordable surgical care

Over 80% of the 15 million people diagnosed with cancer worldwide in 2015 will need surgery, but less than a quarter will have access to proper, safe, affordable surgical care when they need it, according to a major new Commission examining the state of global cancer surgery, published in The Lancet Oncology, and being presented at the 2015 European Cancer Congress in Vienna, Austria.

29 Sep 2015

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

29 Sep 2015

Oncology News and Research

Further Reading

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

U.S 2nd Annual Obesity Summit: 35 major U.S. health societies see how they can treat obesity

Preoperative MRI use increasing in breast cancer

Self-reported fatigue predicts myelodysplastic syndromes survival

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Primary care doctors ill-prepared to cope with rising demand for cancer care in high-income countries

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

Researchers roll out updated online breast cancer risk calculator

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Leading cancer researchers address eight 'big questions'

Stony Brook Children's Hospital follows pain management protocols to treat pain in pediatric patients

Intratumoral morphological diversity of breast cancer not related to chromosome aberrations

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

MedUni Vienna researchers report new strategy for targeted treatment of ovarian cancer

Majority of cancer patients lack access to safe, affordable surgical care

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News